Fluvoxamine (Maléate De) shortage — CA supply status & alternatives

Fluvoxamine (Maléate De)

—

In supply · Australia

Fluvoxamine

In supply · 🇦🇺 Australia · short in🇨🇦 CA🇫🇷 FR

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Fluvoxamine (Maléate De)
Brand names	Fluvoxamine

Therapeutic category	Auto-created by Agence nationale de sécurité du médicament — Disponibilité scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

How long have past shortages lasted? from 1 resolved event

◷

~2 months

Historical pattern from resolved shortage records — not a prediction of this event.

Shortage status by regulator official notices

🇨🇦

Canada

HC · 2h ago

Medium

🇫🇷

France

ANSM · 1d ago

Resolved

Verified timeline regulator events

🇨🇦 6 May 2026

medium reported

🇫🇷 5 May 2026

Shortage resolved

🇫🇷 20 Jan 2026

medium reported

Sources official regulators

🇨🇦

verified 2h ago

verify ↗

🇫🇷

ANSM

verified 1d ago

verify ↗

Mederti Drug Report

Generated 3 July 2026 · Australia market · 2 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.